SCHEMBL5636862

SCHEMBL5636862

COc1ncccc1NC=O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 1/20 0.45
APLNR P35414 1/20 0.44
BTK Q06187 1/20 0.40
TSHR P16473 1/20 0.39
NFE2L2 Q16236 2/20 0.38
ALDH1A1 P00352 2/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ATR Q13535 1/20 0.36
IDH1 O75874 1/20 0.36
PTGES2 Q9H7Z7 1/20 0.36
PAX8 Q06710 1/20 0.36
GFER P55789 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3904232 0.77 SLC22A12 (0.46) SLC22A12APLNRBTKALDH1A1GAA
SCHEMBL22593335 0.76 SLC22A12 (0.44) SLC22A12APLNRBTKNFE2L2ALDH1A1
SCHEMBL5266402 0.76 SLC22A12 (0.44) SLC22A12APLNRBTKNFE2L2ALDH1A1
SCHEMBL13036943 0.76 SLC22A12 (0.44) SLC22A12APLNRBTKALDH1A1GAA
SCHEMBL10430438 0.76 P2RX7 (0.41) TSHRALDH1A1MAPTTDP1MEN1
SCHEMBL5636859 0.75 SLC22A12 (0.45) SLC22A12APLNRBTKNFE2L2ALDH1A1
SCHEMBL28608816 0.75 SLC22A12 (0.42) SLC22A12APLNRBTKTSHRALDH1A1
SCHEMBL31701310 0.75 ALDH1A1 (0.63) TSHRALDH1A1L3MBTL1
Hydrochloric Acid SCHEMBL21598400 0.74 SLC22A12 (0.43) SLC22A12APLNRBTKNFE2L2ALDH1A1
SCHEMBL1725253 0.74 ALDH1A1 (0.49) SLC22A12ALDH1A1GAAMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106414448-B It can be used as the new compound of S100- inhibitor 活跃生物技术有限公司 2019-04-19 CN disclosed
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 US disclosed
EP-1534681-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-06-01 EP disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 US disclosed
WO-2004002960-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists CCR5, CXCR3, CCR2 SLC22A12 1229/4885APLNR 870/4885BTK 1525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.